| Description | Ralitoline (Ralitolinum) is an anticonvulsant with anticancer activity and sodium channel blocking activity. |
| Synonyms | GOE-4942, PD-117818, Ralitolina, CI-946, Ralitolinum |
| molecular weight | 296.77 |
| Molecular formula | C13H13ClN2O2S |
| CAS | 1089085-40-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (185.33 mM) |
| References | 1. Dostal LA, et al. Developmental toxicity study in rats treated with the anticonvulsant, ralitoline. Teratology. 1995 ; 51(1):11-19. 2. Fischer W, et al. Anticonvulsant and sodium channel blocking effects of ralitoline in different screening models. Naunyn Schmiedebergs Arch Pharmacol. 1992 ; 346(4):442-452. 3. Löscher W, et al. Ralitoline: a reevaluation of anticonvulsant profile and determination of "active" plasma concentrations in comparison with prototype antiepileptic drugs in mice. Epilepsia. 1991 ; 32(4):560-568. 4. Rock DM, et al. Ralitoline (CI-946) and CI-953 block sustained repetitive sodium action potentials in cultured mouse spinal cord neurons and displace batrachotoxinin A 20-alpha-benzoate binding in vitro. Epilepsy Res. 1991 ; 8(3):197-203. |